Industry / Brazil
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Teva Outlines Approach To Risk
February 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
On February 21, the world's largest generics company, Israel's Teva Pharmaceutical Industries held its investor day in New York - an event monitored by BMI's pharma team. Teva outlined a strategy that it believes should enable sales growth of 15-18% year-on-year (y-o-y), from US$9.4bn in 2007 to US$19.0-21.5bn by 2012. Here, BMI summarises the themes of the day, and considers how Teva's strategy will play out against our own expectations for the global generics market over the next five